Janet C Lindsey
Overview
Explore the profile of Janet C Lindsey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
2706
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Adiamah M, Poole B, Lindsey J, Kohe S, Morcavallo A, Burte F, et al.
Neuro Oncol
. 2024 Oct;
27(1):237-253.
PMID: 39377369
Background: Group 3 medulloblastoma (MBGRP3) represents around 25% of medulloblastomas and is strongly associated with c-MYC (MYC) amplification, which confers significantly worse patient survival. Although elevated MYC expression is a...
2.
Schwalbe E, Lindsey J, Danilenko M, Hill R, Crosier S, Ryan S, et al.
Neuro Oncol
. 2024 Oct;
27(1):222-236.
PMID: 39377358
Background: MYC/MYCN are the most frequent oncogene amplifications in medulloblastoma (MB) and its primary biomarkers of high-risk (HR) disease. However, while many patients' MYC(N)-amplified tumors are treatment-refractory, some achieve long-term...
3.
Williamson D, Schwalbe E, Hicks D, Aldinger K, Lindsey J, Crosier S, et al.
Cell Rep
. 2022 Aug;
40(5):111162.
PMID: 35926460
Medulloblastoma is currently subclassified into distinct DNA methylation subgroups/subtypes with particular clinico-molecular features. Using RNA sequencing (RNA-seq) in large, well-annotated cohorts of medulloblastoma, we show that transcriptionally group 3 and...
4.
Richardson S, Hill R, Kui C, Lindsey J, Grabovksa Y, Keeling C, et al.
Neuro Oncol
. 2021 Jul;
24(1):153-165.
PMID: 34272868
Background: Less than 5% of medulloblastoma (MB) patients survive following failure of contemporary radiation-based therapies. Understanding the molecular drivers of medulloblastoma relapse (rMB) will be essential to improve outcomes. Initial...
5.
Crosier S, Hicks D, Schwalbe E, Williamson D, Leigh Nicholson S, Smith A, et al.
Neuropathol Appl Neurobiol
. 2021 Apr;
47(6):736-747.
PMID: 33826763
Aims: Application of advanced molecular pathology in rare tumours is hindered by low sample numbers, access to specialised expertise/technologies and tissue/assay QC and rapid reporting requirements. We assessed the feasibility...
6.
Hill R, Richardson S, Schwalbe E, Hicks D, Lindsey J, Crosier S, et al.
Lancet Child Adolesc Health
. 2020 Nov;
4(12):865-874.
PMID: 33222802
Background: Disease relapse occurs in around 30% of children with medulloblastoma, and is almost universally fatal. We aimed to establish whether the clinical and molecular characteristics of the disease at...
7.
Sharma T, Schwalbe E, Williamson D, Sill M, Hovestadt V, Mynarek M, et al.
Acta Neuropathol
. 2019 May;
138(2):309-326.
PMID: 31076851
In 2012, an international consensus paper reported that medulloblastoma comprises four molecular subgroups (WNT, SHH, Group 3, and Group 4), each associated with distinct genomic features and clinical behavior. Independently,...
8.
Izquierdo E, Yuan L, George S, Hubank M, Jones C, Proszek P, et al.
Oncotarget
. 2018 Jan;
8(67):112036-112050.
PMID: 29340109
The implementation of personalised medicine in childhood cancers has been limited by a lack of clinically validated multi-target sequencing approaches specific for paediatric solid tumours. In order to support innovative...
9.
Schwalbe E, Lindsey J, Nakjang S, Crosier S, Smith A, Hicks D, et al.
Lancet Oncol
. 2017 May;
18(7):958-971.
PMID: 28545823
Background: International consensus recognises four medulloblastoma molecular subgroups: WNT (MB), SHH (MB), group 3 (MB), and group 4 (MB), each defined by their characteristic genome-wide transcriptomic and DNA methylomic profiles....
10.
Morrissy A, Garzia L, Shih D, Zuyderduyn S, Huang X, Skowron P, et al.
Nature
. 2016 Jan;
529(7586):351-7.
PMID: 26760213
The development of targeted anti-cancer therapies through the study of cancer genomes is intended to increase survival rates and decrease treatment-related toxicity. We treated a transposon-driven, functional genomic mouse model...